Home › Triple-Negative Breast Cancer › Illinois
Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Illinois
20 pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa mga site sa Illinois.
Mga Lungsod sa Illinois
Opisyal na teksto ng pag-aaral (English)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Chicago Hospital, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06465069PRE-ISPY Phase I/II Oncology Platform Program
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
- UChicago Medicine Orland Park, Orland Park
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT05868226Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Illinois Cancer Specialists (ICS) ( Site 8010), Arlington Heights
- Southern Illinois Hospital Services ( Site 9547), Carterville
- Orchard Healthcare Research Inc. ( Site 0014), Skokie
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- University of Illinois Cancer Center ( Site 0044), Chicago
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06841354Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Northwestern University Feinberg School of Medicine, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Northwestern Medicine, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
- at 3 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT05633654Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Southern Illinois Hospital Services, Carbondale
- Cancer Care Specialist of Illinois, O'Fallon
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07211178SMP-3124LP in Adults With Advanced Solid Tumors
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06526819A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 0280, Chicago
- Decatur Memorial Hospital, Decatur
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06926868A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Northwestern University, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT05005403A Study of LY4175408 in Participants With Advanced Cancer
- The University of Chicago Medical Center (UCMC), Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT07046923Study of XB010 in Subjects With Solid Tumors
- University of Chicago Medical Center, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT06545331A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Northwestern Memorial Hospital, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT04300556I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Chicago, Chicago
- Loyola University, Maywood
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT01042379Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- University of Chicago Medical Center, Chicago
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 29, 2026 · NCT04468061A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- UChicago Medicine Comprehensive Cancer Center, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06908928A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Kellogg Cancer Center, Evanston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2025 · NCT05902988A Study of NX-1607 in Adults With Advanced Malignancies
- University of Chicago, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT05107674CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Illinois Cancer Care, Peoria
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Kababaihan · Na-update Ene 7, 2025 · NCT06230185Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.